Orthofix backs FY25 revenue view $808M-$816M, consensus $813.4M

Backs FY25 adjusted EBITDA view $82M-$86M. The company said, “Pro forma net sales expected to range between $808 million to $816 million, excluding sales from the discontinued M6 product lines. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. Pro forma non-GAAP adjusted EBITDA is expected to be $82 million to $86 million. This range includes the anticipated impact from the discontinuation of the M6 product lines that was previously announced in February 2025. Free cash flow is expected to be positive for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6 product lines.”